Back to top
more

Regeneron Pharmaceuticals, Inc. (REGN)

(Delayed Data from NSDQ)

$299.40 USD

299.40
818,327

-4.42 (-1.45%)

Updated Oct 16, 2019 03:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | C Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Ekta Bagri

Wet AMD Space in Focus: New Drug Approvals & Key Advancements

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

RHHBY BAYRY AGN NVS REGN RGNX

Zacks Equity Research

Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

LLY SNY REGN DERM

Zacks Equity Research

Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

NVS RHHBY BAYRY REGN

Zacks Equity Research

Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

SNY PFE LLY REGN

Zacks Equity Research

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

MRK NVS SNY REGN

Zacks Equity Research

Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.

CLVS BIIB AMGN REGN ZEAL

Zacks Equity Research

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

SNY AMGN ALNY REGN

Zacks Equity Research

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

XEL ILMN REGN TGT TMUS

Mark Vickery

Top Research Reports for Target, Illumina & T-Mobile US

Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS).

XEL TMUS TGT REGN ILMN DD

Zacks Equity Research

Alnylam Focuses on Pipeline Development Amid Competition

Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.

SNY ALNY REGN MDCO

Zacks Equity Research

Alnylam Begins Phase III Study on Onpattro for New Indication

Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.

SNY ALNY MDCO REGN

Zacks Equity Research

Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

SNY AMGN REGN AIMT

Zacks Equity Research

Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

GSK AZN SNY REGN

Zacks Equity Research

Adverum Reports Data From Phase I Wet AMD Study, Stock Down

Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

NVS REGN ADVM EDIT

Zacks Equity Research

Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe

The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.

NVS RHHBY AGN REGN

Zacks Equity Research

Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

REGN

Ekta Bagri

Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

SNY REGN AMGN VRTX FATE ARDX AKTX

Zacks Equity Research

Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study

A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.

MRK SNY REGN ESPR

Zacks Equity Research

Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.

SNY REGN ALXN AMGN

Zacks Equity Research

Inovio (INO) Down More Than 30% in 3 Months: Here's Why

Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.

Zacks Equity Research

Esperion's Drugs in Review Hold Potential, Funds a Concern

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron

REGN GILD CELG VRTX SRPT

Zacks Equity Research

The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier

EL REGN BDX HFC AMAT

Zacks Equity Research

Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More

Key highlights of the past week include drug approvals, and other regulatory and pipeline news.

SRPT REGN CELG VNDA NBRV VRTX GILD

Zacks Equity Research

Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100

Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.

SNY REGN INO ALXN